Kathryn Haskins
Concepts (395)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 79 | 2025 | 3706 | 4.800 |
Why?
| | Autoantigens | 34 | 2025 | 422 | 4.570 |
Why?
| | CD4-Positive T-Lymphocytes | 33 | 2025 | 1098 | 4.430 |
Why?
| | Mice, Inbred NOD | 69 | 2024 | 593 | 3.300 |
Why?
| | Islets of Langerhans | 45 | 2025 | 792 | 3.210 |
Why?
| | Chromogranin A | 9 | 2024 | 42 | 3.070 |
Why?
| | T-Lymphocytes | 53 | 2025 | 1986 | 2.570 |
Why?
| | Epitopes, T-Lymphocyte | 11 | 2025 | 184 | 1.990 |
Why?
| | Receptors, Antigen, T-Cell | 28 | 2021 | 718 | 1.970 |
Why?
| | Insulin | 19 | 2025 | 2448 | 1.970 |
Why?
| | Islet Amyloid Polypeptide | 5 | 2018 | 48 | 1.900 |
Why?
| | Peptides | 17 | 2024 | 976 | 1.760 |
Why?
| | Diabetes Mellitus, Experimental | 15 | 2020 | 199 | 1.570 |
Why?
| | Insulin-Secreting Cells | 9 | 2024 | 375 | 1.500 |
Why?
| | Autoimmunity | 15 | 2022 | 903 | 1.490 |
Why?
| | Peptide Fragments | 12 | 2024 | 693 | 1.400 |
Why?
| | C-Peptide | 6 | 2025 | 163 | 1.370 |
Why?
| | Mice | 94 | 2024 | 17814 | 1.180 |
Why?
| | Clone Cells | 30 | 2018 | 265 | 1.160 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2021 | 386 | 1.150 |
Why?
| | Animals | 103 | 2024 | 37217 | 0.950 |
Why?
| | Epitopes | 13 | 2024 | 475 | 0.950 |
Why?
| | CD40 Antigens | 4 | 2012 | 89 | 0.860 |
Why?
| | Antigen-Presenting Cells | 8 | 2014 | 157 | 0.810 |
Why?
| | Islets of Langerhans Transplantation | 6 | 2022 | 65 | 0.810 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 2019 | 136 | 0.790 |
Why?
| | Adoptive Transfer | 16 | 2015 | 222 | 0.760 |
Why?
| | Lymphocyte Activation | 16 | 2020 | 1148 | 0.740 |
Why?
| | Mice, SCID | 15 | 2018 | 368 | 0.680 |
Why?
| | Th1 Cells | 5 | 2009 | 139 | 0.660 |
Why?
| | Graft Survival | 1 | 2022 | 491 | 0.620 |
Why?
| | CD4 Antigens | 5 | 2013 | 141 | 0.590 |
Why?
| | Cells, Cultured | 13 | 2020 | 4181 | 0.570 |
Why?
| | Nanoparticles | 3 | 2022 | 469 | 0.560 |
Why?
| | Mice, Transgenic | 20 | 2021 | 2172 | 0.540 |
Why?
| | Mice, Inbred BALB C | 18 | 2016 | 1262 | 0.540 |
Why?
| | Pancreas | 6 | 2013 | 322 | 0.540 |
Why?
| | Recombinant Fusion Proteins | 3 | 2019 | 663 | 0.530 |
Why?
| | Recombination, Genetic | 1 | 2018 | 206 | 0.520 |
Why?
| | CD8-Positive T-Lymphocytes | 8 | 2025 | 905 | 0.520 |
Why?
| | Histocompatibility Antigens Class II | 6 | 2013 | 366 | 0.500 |
Why?
| | Macrophages | 6 | 2009 | 1543 | 0.490 |
Why?
| | CD40 Ligand | 2 | 2012 | 41 | 0.440 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 9 | 2012 | 334 | 0.440 |
Why?
| | Immunotherapy | 1 | 2019 | 634 | 0.430 |
Why?
| | Autoimmune Diseases | 7 | 2018 | 454 | 0.430 |
Why?
| | Antigen Presentation | 3 | 2021 | 219 | 0.410 |
Why?
| | Immune Tolerance | 5 | 2021 | 366 | 0.410 |
Why?
| | Prediabetic State | 3 | 2013 | 248 | 0.410 |
Why?
| | Histocompatibility Antigens | 3 | 2011 | 106 | 0.400 |
Why?
| | Th2 Cells | 2 | 2007 | 177 | 0.400 |
Why?
| | Spleen | 11 | 2013 | 523 | 0.380 |
Why?
| | Mice, Knockout | 8 | 2021 | 3028 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2007 | 1244 | 0.360 |
Why?
| | HLA-A2 Antigen | 2 | 2025 | 49 | 0.360 |
Why?
| | Oxidative Stress | 4 | 2007 | 1316 | 0.340 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 205 | 0.330 |
Why?
| | Flow Cytometry | 8 | 2015 | 1192 | 0.320 |
Why?
| | Specific Pathogen-Free Organisms | 3 | 2018 | 60 | 0.310 |
Why?
| | Macrophage Activation | 2 | 2007 | 199 | 0.310 |
Why?
| | Antigens, CD | 3 | 2008 | 536 | 0.310 |
Why?
| | Amino Acid Sequence | 8 | 2016 | 2155 | 0.300 |
Why?
| | Mass Spectrometry | 4 | 2023 | 734 | 0.290 |
Why?
| | Diabetes Mellitus | 5 | 2014 | 1068 | 0.290 |
Why?
| | Cytokines | 9 | 2009 | 2080 | 0.290 |
Why?
| | Interferon-gamma | 8 | 2020 | 786 | 0.290 |
Why?
| | Receptors, CCR8 | 1 | 2007 | 2 | 0.280 |
Why?
| | Chemokine CCL1 | 1 | 2007 | 2 | 0.280 |
Why?
| | Autoantibodies | 6 | 2025 | 1456 | 0.280 |
Why?
| | Major Histocompatibility Complex | 10 | 2006 | 232 | 0.260 |
Why?
| | HLA-DQ Antigens | 3 | 2021 | 177 | 0.260 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 488 | 0.250 |
Why?
| | Cell Line | 13 | 2013 | 2876 | 0.240 |
Why?
| | Humans | 39 | 2025 | 138651 | 0.220 |
Why?
| | T-Lymphocyte Subsets | 4 | 2003 | 415 | 0.210 |
Why?
| | Thymus Gland | 5 | 2015 | 314 | 0.210 |
Why?
| | Tyrosine | 2 | 2005 | 227 | 0.210 |
Why?
| | Disease Models, Animal | 3 | 2019 | 4315 | 0.210 |
Why?
| | Antibodies, Monoclonal | 12 | 2008 | 1436 | 0.200 |
Why?
| | Transglutaminases | 2 | 2013 | 155 | 0.190 |
Why?
| | Female | 32 | 2025 | 73763 | 0.180 |
Why?
| | Regeneration | 1 | 2004 | 198 | 0.180 |
Why?
| | Cell Movement | 4 | 2014 | 969 | 0.180 |
Why?
| | CD11c Antigen | 2 | 2019 | 41 | 0.180 |
Why?
| | Metalloporphyrins | 1 | 2002 | 105 | 0.180 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 623 | 0.170 |
Why?
| | B-Lymphocytes | 3 | 2015 | 855 | 0.170 |
Why?
| | Crosses, Genetic | 3 | 2018 | 133 | 0.170 |
Why?
| | Molecular Sequence Data | 4 | 2016 | 2923 | 0.170 |
Why?
| | Antigens, Surface | 2 | 2000 | 154 | 0.160 |
Why?
| | Transgenes | 1 | 2001 | 185 | 0.160 |
Why?
| | Gene Products, gag | 1 | 2020 | 38 | 0.160 |
Why?
| | Antigens, Differentiation | 1 | 2000 | 82 | 0.160 |
Why?
| | Glutamate Decarboxylase | 5 | 2008 | 165 | 0.160 |
Why?
| | Endogenous Retroviruses | 1 | 2020 | 38 | 0.160 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 110 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2019 | 2480 | 0.150 |
Why?
| | Mice, Inbred Strains | 9 | 1998 | 411 | 0.150 |
Why?
| | Insulinoma | 2 | 2002 | 27 | 0.150 |
Why?
| | Recurrence | 1 | 2022 | 1084 | 0.150 |
Why?
| | Celiac Disease | 1 | 2021 | 291 | 0.140 |
Why?
| | Immunoconjugates | 1 | 2000 | 123 | 0.140 |
Why?
| | Animals, Genetically Modified | 1 | 2019 | 242 | 0.140 |
Why?
| | Lymphoid Tissue | 1 | 2018 | 79 | 0.140 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 199 | 0.140 |
Why?
| | Exocytosis | 1 | 2018 | 88 | 0.140 |
Why?
| | Cytoplasmic Granules | 3 | 2000 | 93 | 0.140 |
Why?
| | Immune System | 1 | 2019 | 181 | 0.140 |
Why?
| | Chromatography, Gel | 2 | 2012 | 130 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2490 | 0.140 |
Why?
| | Leukocytes | 1 | 1998 | 307 | 0.130 |
Why?
| | Cell Differentiation | 4 | 2020 | 1992 | 0.130 |
Why?
| | Mice, Inbred C57BL | 6 | 2015 | 5798 | 0.130 |
Why?
| | Cell Division | 4 | 2004 | 794 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2002 | 224 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 849 | 0.120 |
Why?
| | Diabetic Angiopathies | 2 | 2011 | 250 | 0.120 |
Why?
| | Male | 21 | 2025 | 68260 | 0.120 |
Why?
| | Hybridomas | 11 | 2009 | 236 | 0.120 |
Why?
| | Biocompatible Materials | 2 | 2012 | 425 | 0.110 |
Why?
| | Microsatellite Repeats | 1 | 2015 | 159 | 0.110 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 2007 | 97 | 0.110 |
Why?
| | Serine Endopeptidases | 1 | 2015 | 119 | 0.110 |
Why?
| | Disease Progression | 3 | 2019 | 2749 | 0.110 |
Why?
| | CTLA-4 Antigen | 2 | 2008 | 98 | 0.110 |
Why?
| | Antigens, Neoplasm | 2 | 1994 | 316 | 0.110 |
Why?
| | Nitric Oxide | 3 | 2007 | 893 | 0.110 |
Why?
| | Histocompatibility Testing | 1 | 2013 | 123 | 0.100 |
Why?
| | Dendritic Cells | 2 | 2012 | 491 | 0.100 |
Why?
| | Insulin, Regular, Human | 2 | 2024 | 48 | 0.100 |
Why?
| | Signal Transduction | 5 | 2012 | 5086 | 0.100 |
Why?
| | Microscopy, Fluorescence | 2 | 2012 | 414 | 0.100 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.100 |
Why?
| | Citrulline | 1 | 2013 | 45 | 0.100 |
Why?
| | Amino Acid Motifs | 2 | 2010 | 225 | 0.090 |
Why?
| | Proteomics | 2 | 2022 | 1110 | 0.090 |
Why?
| | Fibrinogen | 1 | 2013 | 173 | 0.090 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2012 | 51 | 0.090 |
Why?
| | Interleukin-2 | 4 | 2000 | 451 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2013 | 492 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2012 | 136 | 0.090 |
Why?
| | Arthritis, Experimental | 1 | 2013 | 141 | 0.090 |
Why?
| | Alleles | 2 | 2025 | 887 | 0.090 |
Why?
| | Antigens | 2 | 2024 | 356 | 0.090 |
Why?
| | Child | 7 | 2025 | 21921 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2012 | 164 | 0.090 |
Why?
| | Lymphocyte Transfusion | 3 | 2005 | 21 | 0.080 |
Why?
| | Complementarity Determining Regions | 2 | 2012 | 51 | 0.080 |
Why?
| | Immunodominant Epitopes | 2 | 2009 | 27 | 0.080 |
Why?
| | Carotid Artery Diseases | 1 | 2011 | 61 | 0.080 |
Why?
| | HLA-A Antigens | 1 | 2010 | 57 | 0.080 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 935 | 0.080 |
Why?
| | Ovalbumin | 3 | 2021 | 194 | 0.080 |
Why?
| | RNA, Messenger | 4 | 2005 | 2815 | 0.080 |
Why?
| | Up-Regulation | 2 | 2013 | 851 | 0.080 |
Why?
| | Receptors, Interleukin-2 | 2 | 2000 | 66 | 0.080 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 2006 | 27 | 0.080 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 57 | 0.080 |
Why?
| | Chromosome Mapping | 2 | 2004 | 502 | 0.070 |
Why?
| | Adolescent | 5 | 2025 | 21564 | 0.070 |
Why?
| | CD28 Antigens | 1 | 2008 | 56 | 0.070 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2008 | 54 | 0.070 |
Why?
| | Gene Expression | 1 | 2013 | 1488 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2004 | 349 | 0.070 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2007 | 10 | 0.070 |
Why?
| | Polyethylene Glycols | 3 | 2012 | 631 | 0.070 |
Why?
| | Organ Specificity | 1 | 2008 | 310 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 303 | 0.070 |
Why?
| | CD11b Antigen | 1 | 2007 | 63 | 0.070 |
Why?
| | Macrophages, Peritoneal | 1 | 2007 | 95 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2007 | 166 | 0.070 |
Why?
| | Chemotaxis | 1 | 2007 | 133 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 4092 | 0.060 |
Why?
| | Adult | 6 | 2025 | 38201 | 0.060 |
Why?
| | Hydrogels | 3 | 2012 | 680 | 0.060 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 2 | 2004 | 21 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 984 | 0.060 |
Why?
| | Mice, Mutant Strains | 3 | 1991 | 309 | 0.060 |
Why?
| | Pancreatic Neoplasms | 1 | 1994 | 857 | 0.060 |
Why?
| | Prostaglandins | 1 | 2005 | 101 | 0.060 |
Why?
| | Young Adult | 4 | 2025 | 13305 | 0.060 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2025 | 37 | 0.060 |
Why?
| | Genes, T-Cell Receptor | 1 | 2005 | 9 | 0.060 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 49 | 0.060 |
Why?
| | Receptors, Cytokine | 1 | 2005 | 36 | 0.060 |
Why?
| | Species Specificity | 4 | 2006 | 581 | 0.060 |
Why?
| | Immunoglobulin Allotypes | 1 | 1984 | 9 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 178 | 0.060 |
Why?
| | Lymphocyte Depletion | 3 | 2000 | 135 | 0.050 |
Why?
| | Mice, Congenic | 1 | 2004 | 23 | 0.050 |
Why?
| | Proinsulin | 1 | 2024 | 52 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2013 | 1164 | 0.050 |
Why?
| | Chemokines | 1 | 2005 | 226 | 0.050 |
Why?
| | Molecular Mimicry | 1 | 2003 | 42 | 0.050 |
Why?
| | Rats | 5 | 2000 | 5594 | 0.050 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2000 | 336 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 761 | 0.050 |
Why?
| | Aging | 4 | 2005 | 1855 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 80 | 0.050 |
Why?
| | Genes, RAG-1 | 1 | 2003 | 12 | 0.050 |
Why?
| | DNA Primers | 1 | 2004 | 508 | 0.050 |
Why?
| | Cathepsin D | 1 | 2022 | 17 | 0.050 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 145 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 1997 | 898 | 0.050 |
Why?
| | Extracellular Matrix | 1 | 2007 | 541 | 0.050 |
Why?
| | Solubility | 2 | 2000 | 242 | 0.050 |
Why?
| | Antibody Specificity | 5 | 1996 | 187 | 0.050 |
Why?
| | Vasodilation | 1 | 2005 | 509 | 0.050 |
Why?
| | Respiratory Burst | 1 | 2002 | 19 | 0.050 |
Why?
| | Glucose | 3 | 2007 | 1032 | 0.050 |
Why?
| | Molecular Weight | 5 | 2006 | 327 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2023 | 1092 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2004 | 626 | 0.040 |
Why?
| | Cytoprotection | 1 | 2021 | 57 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2003 | 352 | 0.040 |
Why?
| | Leukemia L1210 | 1 | 2001 | 8 | 0.040 |
Why?
| | K562 Cells | 1 | 2021 | 91 | 0.040 |
Why?
| | L-Selectin | 1 | 2001 | 24 | 0.040 |
Why?
| | Interphase | 1 | 2001 | 33 | 0.040 |
Why?
| | Perforin | 1 | 2001 | 19 | 0.040 |
Why?
| | Phosphotyrosine | 1 | 2001 | 40 | 0.040 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2001 | 15 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2021 | 179 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2002 | 151 | 0.040 |
Why?
| | fas Receptor | 1 | 2001 | 97 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2001 | 202 | 0.040 |
Why?
| | Integrins | 1 | 2001 | 95 | 0.040 |
Why?
| | Chromatography, Ion Exchange | 1 | 2000 | 53 | 0.040 |
Why?
| | Detergents | 1 | 2000 | 45 | 0.040 |
Why?
| | Hemocyanins | 1 | 2000 | 61 | 0.040 |
Why?
| | Heat-Shock Proteins | 2 | 2001 | 142 | 0.040 |
Why?
| | Abatacept | 1 | 2000 | 56 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 130 | 0.040 |
Why?
| | Cell Lineage | 1 | 2021 | 350 | 0.040 |
Why?
| | Mice, Inbred DBA | 3 | 2013 | 199 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 2 | 1997 | 167 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 354 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2001 | 327 | 0.040 |
Why?
| | Clonal Anergy | 1 | 1999 | 52 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1233 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2590 | 0.040 |
Why?
| | Cell-Derived Microparticles | 1 | 2020 | 71 | 0.040 |
Why?
| | Viral Proteins | 1 | 2021 | 362 | 0.040 |
Why?
| | Macromolecular Substances | 3 | 1991 | 226 | 0.040 |
Why?
| | Pancreatitis | 1 | 2000 | 133 | 0.040 |
Why?
| | Transfection | 1 | 2001 | 941 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2001 | 230 | 0.040 |
Why?
| | Interleukin-13 | 1 | 1999 | 148 | 0.040 |
Why?
| | Intracellular Membranes | 1 | 1998 | 82 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2002 | 888 | 0.040 |
Why?
| | Muramidase | 1 | 1998 | 79 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2001 | 499 | 0.040 |
Why?
| | NF-kappa B | 1 | 2002 | 678 | 0.040 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1997 | 18 | 0.030 |
Why?
| | Antibodies | 1 | 2000 | 404 | 0.030 |
Why?
| | Rats, Inbred Strains | 2 | 1990 | 345 | 0.030 |
Why?
| | Materials Testing | 2 | 2012 | 350 | 0.030 |
Why?
| | Obesity | 1 | 1990 | 2962 | 0.030 |
Why?
| | Multigene Family | 1 | 1997 | 201 | 0.030 |
Why?
| | Cloning, Molecular | 3 | 2003 | 533 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 2000 | 956 | 0.030 |
Why?
| | Animals, Newborn | 3 | 2005 | 859 | 0.030 |
Why?
| | Cell Membrane | 1 | 2000 | 716 | 0.030 |
Why?
| | Glutathione | 1 | 1998 | 355 | 0.030 |
Why?
| | Phosphorylation | 1 | 2001 | 1760 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 571 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 1996 | 100 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1996 | 174 | 0.030 |
Why?
| | NADPH Oxidases | 2 | 2007 | 140 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2000 | 1731 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1471 | 0.030 |
Why?
| | Immunization | 2 | 1996 | 405 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2001 | 2030 | 0.030 |
Why?
| | Thymocytes | 1 | 2015 | 35 | 0.030 |
Why?
| | Stromal Cells | 1 | 2015 | 112 | 0.030 |
Why?
| | Mice, Inbred AKR | 4 | 1997 | 37 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1995 | 288 | 0.030 |
Why?
| | Centrifugation, Density Gradient | 1 | 1994 | 40 | 0.030 |
Why?
| | Culture Techniques | 1 | 1994 | 74 | 0.030 |
Why?
| | Cell Fractionation | 1 | 1994 | 54 | 0.030 |
Why?
| | Journal Impact Factor | 1 | 2014 | 28 | 0.030 |
Why?
| | Binding Sites, Antibody | 2 | 1984 | 41 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 2 | 1984 | 54 | 0.030 |
Why?
| | Genetic Markers | 1 | 1995 | 342 | 0.030 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 1993 | 16 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2000 | 1145 | 0.030 |
Why?
| | Rats, Inbred BB | 1 | 1993 | 5 | 0.030 |
Why?
| | Middle Aged | 2 | 2025 | 33604 | 0.030 |
Why?
| | Cell Survival | 2 | 2007 | 1123 | 0.020 |
Why?
| | Collagen Type II | 1 | 2013 | 55 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1992 | 75 | 0.020 |
Why?
| | Trinitrobenzenes | 1 | 1992 | 14 | 0.020 |
Why?
| | Adenoma, Islet Cell | 1 | 1992 | 6 | 0.020 |
Why?
| | Hybrid Cells | 1 | 1992 | 48 | 0.020 |
Why?
| | Haptens | 1 | 1992 | 22 | 0.020 |
Why?
| | Immunity, Innate | 1 | 1998 | 824 | 0.020 |
Why?
| | Immunosuppressive Agents | 2 | 2012 | 849 | 0.020 |
Why?
| | Publishing | 1 | 2014 | 144 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 1993 | 1047 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 4 | 1983 | 27 | 0.020 |
Why?
| | Kinetics | 1 | 1995 | 1645 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 1992 | 133 | 0.020 |
Why?
| | Periodicals as Topic | 1 | 2014 | 212 | 0.020 |
Why?
| | Base Sequence | 2 | 1993 | 2174 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2012 | 241 | 0.020 |
Why?
| | Neointima | 1 | 2011 | 15 | 0.020 |
Why?
| | Mice, Nude | 1 | 1993 | 688 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 166 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 1990 | 54 | 0.020 |
Why?
| | Colorado | 1 | 2001 | 4555 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2011 | 280 | 0.020 |
Why?
| | Collagen | 1 | 2013 | 459 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2012 | 304 | 0.020 |
Why?
| | Age Factors | 2 | 1995 | 3256 | 0.020 |
Why?
| | Sex Factors | 1 | 1995 | 2044 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 1989 | 75 | 0.020 |
Why?
| | Leukemia, Lymphoid | 2 | 2006 | 27 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2009 | 61 | 0.020 |
Why?
| | Pituitary Gland | 1 | 1989 | 150 | 0.020 |
Why?
| | Trypsin | 2 | 2006 | 76 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2009 | 238 | 0.020 |
Why?
| | Lymphokines | 1 | 1988 | 133 | 0.020 |
Why?
| | Cell Separation | 1 | 1988 | 317 | 0.020 |
Why?
| | Tissue Distribution | 2 | 1985 | 330 | 0.020 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 184 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1992 | 655 | 0.020 |
Why?
| | Salivary Glands | 1 | 2006 | 34 | 0.020 |
Why?
| | Mucoproteins | 1 | 2005 | 8 | 0.020 |
Why?
| | Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2005 | 3 | 0.020 |
Why?
| | Acetophenones | 1 | 2005 | 14 | 0.020 |
Why?
| | Onium Compounds | 1 | 2005 | 8 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 78 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 331 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2005 | 83 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2007 | 466 | 0.010 |
Why?
| | Drug Compounding | 1 | 2005 | 101 | 0.010 |
Why?
| | Acetylcholine | 1 | 2005 | 203 | 0.010 |
Why?
| | History, 20th Century | 1 | 2006 | 323 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1984 | 98 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 1993 | 2339 | 0.010 |
Why?
| | Isoelectric Point | 1 | 1984 | 23 | 0.010 |
Why?
| | Disulfides | 1 | 1984 | 97 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2003 | 12 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2003 | 23 | 0.010 |
Why?
| | Chemical Precipitation | 1 | 1983 | 38 | 0.010 |
Why?
| | Aorta | 1 | 2005 | 418 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2225 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2003 | 274 | 0.010 |
Why?
| | Peptide Library | 1 | 2002 | 95 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 1983 | 212 | 0.010 |
Why?
| | Inflammation | 2 | 2006 | 2850 | 0.010 |
Why?
| | Haplotypes | 1 | 2003 | 495 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2005 | 1076 | 0.010 |
Why?
| | Homeostasis | 1 | 2005 | 614 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2001 | 209 | 0.010 |
Why?
| | Time Factors | 1 | 2012 | 6851 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2000 | 45 | 0.010 |
Why?
| | Ligands | 1 | 2002 | 665 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 2000 | 114 | 0.010 |
Why?
| | Blood Glucose | 3 | 1999 | 2239 | 0.010 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2000 | 174 | 0.010 |
Why?
| | Pancreatic Ducts | 1 | 2000 | 79 | 0.010 |
Why?
| | Nitric Oxide Synthase | 1 | 2000 | 242 | 0.010 |
Why?
| | Cell Transplantation | 1 | 1999 | 39 | 0.010 |
Why?
| | Complement C5 | 1 | 1999 | 80 | 0.010 |
Why?
| | H-2 Antigens | 1 | 1999 | 115 | 0.010 |
Why?
| | Epithelium | 1 | 2000 | 316 | 0.010 |
Why?
| | Models, Immunological | 1 | 1999 | 101 | 0.010 |
Why?
| | Rats, Wistar | 1 | 2000 | 453 | 0.010 |
Why?
| | Interleukin-4 | 1 | 1999 | 214 | 0.010 |
Why?
| | Conalbumin | 1 | 1997 | 3 | 0.010 |
Why?
| | Immune Sera | 1 | 1997 | 83 | 0.010 |
Why?
| | Apoptosis | 1 | 2007 | 2546 | 0.010 |
Why?
| | Superantigens | 1 | 1997 | 70 | 0.010 |
Why?
| | Enterotoxins | 1 | 1997 | 88 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 1999 | 331 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1997 | 162 | 0.010 |
Why?
| | Genes, Immunoglobulin | 1 | 1996 | 28 | 0.010 |
Why?
| | Spodoptera | 1 | 1996 | 40 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2000 | 847 | 0.010 |
Why?
| | Baculoviridae | 1 | 1996 | 43 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 509 | 0.010 |
Why?
| | Antibody Formation | 1 | 1996 | 298 | 0.010 |
Why?
| | Pregnancy | 2 | 1997 | 6829 | 0.010 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 433 | 0.010 |
Why?
| | Submandibular Gland | 1 | 1993 | 20 | 0.010 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 143 | 0.010 |
Why?
| | Globins | 1 | 1989 | 21 | 0.000 |
Why?
| | Antigens, Ly | 1 | 1984 | 43 | 0.000 |
Why?
| | Isoelectric Focusing | 1 | 1983 | 30 | 0.000 |
Why?
| | Chickens | 1 | 1983 | 189 | 0.000 |
Why?
| | Immunologic Techniques | 1 | 1983 | 39 | 0.000 |
Why?
| | Birds | 1 | 1983 | 95 | 0.000 |
Why?
| | Molecular Conformation | 1 | 1983 | 147 | 0.000 |
Why?
| | DNA | 1 | 1989 | 1438 | 0.000 |
Why?
|
|
Haskins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|